Fastidious intracellular bacteria as causal agents of community-acquired pneumonia

References

• British Thoracic Society guidelines for the management of community acquired pneumonia in adults. Thorax56(Suppl. 4), IV1–64 (2001).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society guidelines for the management of community acquired pneumonia in childhood. Thorax57(Suppl. 1), i1–i24 (2002).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch. Intern. Med.162(6), 682–688 (2002).
   PubMed Web of Science ®Google Scholar
• Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med.164(6), 637–644 (2004).
   PubMedGoogle Scholar
• Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA278(23), 2080–2084 (1997).
   PubMed Web of Science ®Google Scholar
• Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin. Microbiol. Infect.12(Suppl. 3), 12–24 (2006).
   PubMed Web of Science ®Google Scholar
• Murdoch DR, Chambers ST. Atypical pneumonia – time to breathe new life into a useful term? Lancet Infect. Dis.9(8), 512–519 (2009).
   PubMed Web of Science ®Google Scholar
• Arnold FW, Summersgill JT, Lajoie AS et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am. J. Respir. Crit. Care Med.175(10), 1086–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Is activity against “atypical” pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin. Infect. Dis.47(Suppl. 3), S232–S236 (2008).
   PubMed Web of Science ®Google Scholar
• Bochud PY, Moser F, Erard P et al. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore)80(2), 75–87 (2001).
   PubMed Web of Science ®Google Scholar
• Tsolia MN, Psarras S, Bossios A et al. Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin. Infect. Dis.39(5), 681–686 (2004).
   PubMed Web of Science ®Google Scholar
• File TM. Community-acquired pneumonia. Lancet362(9400), 1991–2001 (2003).
   PubMed Web of Science ®Google Scholar
• Fang GD, Yu VL, Vickers RM. Disease due to the Legionellaceae (other than Legionella pneumophila). Historical, microbiological, clinical, and epidemiological review. Medicine (Baltimore)68(2), 116–132 (1989).
   PubMed Web of Science ®Google Scholar
• Muder RR, Yu VL. Infection due to Legionella species other than L. pneumophila. Clin. Infect. Dis.35(8), 990–998 (2002).
   PubMed Web of Science ®Google Scholar
• Yu VL, Plouffe JF, Pastoris MC et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J. Infect. Dis.186(1), 127–128 (2002).
   PubMed Web of Science ®Google Scholar
• Lamoth F, Greub G. Amoebal pathogens as emerging agents of pneumonia. FEMS Microbiol. Rev.34, 260–280 (2010).
   PubMed Web of Science ®Google Scholar
• Fraser DW, Tsai TR, Orenstein W et al. Legionnaires’ disease: description of an epidemic of pneumonia. N. Engl. J. Med.297(22), 1189–1197 (1977).
   PubMed Web of Science ®Google Scholar
• McDade JE, Shepard CC, Fraser DW, Tsai TR, Redus MA, Dowdle WR. Legionnaires’ disease: isolation of a bacterium and demonstration of its role in other respiratory disease. N. Engl. J. Med.297(22), 1197–1203 (1977).
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Steigerwalt AG, McDade JE. Classification of the Legionnaires’ disease bacterium: Legionella pneumophila, genus novum, species nova, of the family Legionellaceae, familia nova. Ann. Intern. Med.90(4), 656–658 (1979).
   PubMed Web of Science ®Google Scholar
• Rowbotham TJ. Preliminary report on the pathogenicity of Legionella pneumophila for freshwater and soil amoebae. J. Clin. Pathol.33(12), 1179–1183 (1980).
   PubMed Web of Science ®Google Scholar
• Rowbotham TJ. Isolation of Legionella pneumophila from clinical specimens via amoebae, and the interaction of those and other isolates with amoebae. J. Clin. Pathol.36(9), 978–986 (1983).
   PubMed Web of Science ®Google Scholar
• Rowbotham TJ. Current views on the relationships between amoebae, legionellae and man. Isr J. Med. Sci.22(9), 678–689 (1986).
   PubMedGoogle Scholar
• Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur. Respir. J.36(Suppl.), S20–S27 (2002).
   Google Scholar
• Neil K, Berkelman R. Increasing incidence of legionellosis in the United States, 1990–2005: changing epidemiologic trends. Clin. Infect. Dis.47(5), 591–599 (2008).
   PubMed Web of Science ®Google Scholar
• Adeleke AA, Fields BS, Benson RF et al. Legionella drozanskii sp. nov., Legionella rowbothamii sp. nov. and Legionella fallonii sp. nov.: three unusual new Legionella species. Int. J. Syst. Evol. Microbiol.51(Pt 3), 1151–1160 (2001).
   PubMedGoogle Scholar
• Benson RF, Fields BS. Classification of the genus Legionella. Semin. Respir. Infect.13(2), 90–99 (1998).
   PubMedGoogle Scholar
• Benin AL, Benson RF, Besser RE. Trends in legionnaires disease, 1980–1998: declining mortality and new patterns of diagnosis. Clin. Infect. Dis.35(9), 1039–1046 (2002).
   PubMed Web of Science ®Google Scholar
• Phares CR, Wangroongsarb P, Chantra S et al. Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand. Clin. Infect. Dis.45(12), e147–e155 (2007).
   PubMed Web of Science ®Google Scholar
• Adeleke A, Pruckler J, Benson R, Rowbotham T, Halablab M, Fields B. Legionella-like amebal pathogens – phylogenetic status and possible role in respiratory disease. Emerg. Infect. Dis.2(3), 225–230 (1996).
   PubMedGoogle Scholar
• Fernandez-Sabe N, Roson B, Carratala J, Dorca J, Manresa F, Gudiol F. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. Clin. Infect. Dis.37(4), 483–489 (2003).
   PubMed Web of Science ®Google Scholar
• Murdoch DR. Diagnosis of Legionella infection. Clin. Infect. Dis.36(1), 64–69 (2003).
   PubMed Web of Science ®Google Scholar
• Ingram JG, Plouffe JF. Danger of sputum purulence screens in culture of Legionella species. J. Clin. Microbiol.32(1), 209–210 (1994).
   PubMedGoogle Scholar
• Shimada T, Noguchi Y, Jackson JL et al. Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest136(6), 1576–1585 (2009).
   PubMed Web of Science ®Google Scholar
• Kohler RB, Winn WC Jr, Wheat LJ. Onset and duration of urinary antigen excretion in Legionnaires disease. J. Clin. Microbiol.20(4), 605–607 (1984).
   PubMed Web of Science ®Google Scholar
• Diederen BM. Legionella spp. and Legionnaires’ disease. J. Infect.56(1), 1–12 (2008).
   PubMed Web of Science ®Google Scholar
• Fields BS, Benson RF, Besser RE. Legionella and Legionnaires’ disease: 25 years of investigation. Clin. Microbiol. Rev.15(3), 506–526 (2002).
   PubMed Web of Science ®Google Scholar
• Formica N, Yates M, Beers M et al. The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires’ disease. Epidemiol. Infect.127(2), 275–280 (2001).
   PubMed Web of Science ®Google Scholar
• Wever PC, Notermans DW, Tulevski II, Schattenkerk JK, de Jong MD. Detection of Legionella pneumophila serogroup 1 antigen in bronchoalveolar lavage fluid by an immunochromatographic assay. J. Clin. Microbiol.41(5), 2265 (2003).
   PubMedGoogle Scholar
• Dominguez J, Gali N, Blanco S et al. Assessment of a new test to detect Legionella urinary antigen for the diagnosis of Legionnaires’ Disease. Diagn. Microbiol. Infect. Dis.41(4), 199–203 (2001).
   PubMedGoogle Scholar
• Helbig JH, Uldum SA, Bernander S et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires’ disease. J. Clin. Microbiol.41(2), 838–840 (2003).
   PubMedGoogle Scholar
• Plouffe JF, File TM Jr, Breiman RF et al. Reevaluation of the definition of Legionnaires’ disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin. Infect. Dis.20(5), 1286–1291 (1995).
   PubMedGoogle Scholar
• Tronel H, Hartemann P. Overview of diagnostic and detection methods for legionellosis and Legionella spp. Lett. Appl. Microbiol.48(6), 653–656 (2009).
   PubMedGoogle Scholar
• Murdoch DR, Walford EJ, Jennings LC et al. Use of the polymerase chain reaction to detect Legionella DNA in urine and serum samples from patients with pneumonia. Clin. Infect. Dis.23(3), 475–480 (1996).
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Ahkee S, Tolentino A, Miller RD, Summersgill JT. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn. Microbiol. Infect. Dis.24(1), 7–14 (1996).
   PubMed Web of Science ®Google Scholar
• Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur. J. Clin. Microbiol. Infect. Dis.15(4), 286–290 (1996).
   PubMed Web of Science ®Google Scholar
• Fraser DW, Wachsmuth I, Bopp C, Feeley JC, Tsai TF. Antibiotic treatment of guinea-pigs infected with agent of Legionnaires’ disease. Lancet1(8057), 175–178 (1978).
   PubMed Web of Science ®Google Scholar
• Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires’ disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore)59(3), 188–205 (1980).
   PubMed Web of Science ®Google Scholar
• Daisy JA, Benson CE, McKitrick J, Friedman HM. Intracellular replication of Legionella pneumophila. J. Infect. Dis.143(3), 460–464 (1981).
   PubMedGoogle Scholar
• Horwitz MA, Silverstein SC. Legionnaires’ disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes. J. Clin. Invest.66(3), 441–450 (1980).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Silverstein SC. Intracellular multiplication of Legionnaires’ disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J. Clin. Invest.71(1), 15–26 (1983).
   PubMed Web of Science ®Google Scholar
• Wong MC, Ewing EP Jr, Callaway CS, Peacock WL Jr. Intracellular multiplication of Legionella pneumophila in cultured human embryonic lung fibroblasts. Infect. Immun.28(3), 1014–1018 (1980).
   PubMedGoogle Scholar
• Fitzgeorge RB, Gibson DH, Jepras R, Baskerville A. Studies on ciprofloxacin therapy of experimental Legionnaires’ disease. J. Infect.10(3), 194–203 (1985).
   PubMedGoogle Scholar
• Greenwood D, Laverick A. Activities of newer quinolones against Legionella group organisms. Lancet2(8344), 279–280 (1983).
   PubMedGoogle Scholar
• Unertl KE, Lenhart FP, Forst H et al. Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. Am. J. Med.87(5A), S128–S131 (1989).
   Web of Science ®Google Scholar
• Baltch AL, Smith RP, Franke MA, Michelsen PB. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob. Agents Chemother.42(12), 3153–3156 (1998).
   PubMed Web of Science ®Google Scholar
• Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J. Antimicrob. Chemother.56(1), 104–109 (2005).
   PubMed Web of Science ®Google Scholar
• Fitzgeorge RB. The effect of antibiotics on the growth of Legionella pneumophila in guinea-pig alveolar phagocytes infected in vivo by an aerosol. J. Infect.10(3), 189–193 (1985).
   PubMedGoogle Scholar
• Fitzgeorge RB, Featherstone AS, Baskerville A. The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes. J. Antimicrob. Chemother.22(Suppl. C), 53–57 (1988).
   PubMedGoogle Scholar
• Havlichek D, Saravolatz L, Pohlod D. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob. Agents Chemother.31(10), 1529–1534 (1987).
   PubMed Web of Science ®Google Scholar
• Kitsukawa K, Hara J, Saito A. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents. J. Antimicrob. Chemother.27(3), 343–353 (1991).
   PubMed Web of Science ®Google Scholar
• Pedro-Botet L, Yu VL. Legionella: macrolides or quinolones? Clin. Microbiol. Infect.12(Suppl. 3), 25–30 (2006).
   PubMed Web of Science ®Google Scholar
• Stout JE, Arnold B, Yu VL. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn. Microbiol. Infect. Dis.30(1), 37–43 (1998).
   PubMedGoogle Scholar
• Stout JE, Sens K, Mietzner S, Obman A, Yu VL. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int. J. Antimicrob. Agents25(4), 302–307 (2005).
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Edelstein MA. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob. Agents Chemother.35(1), 180–181 (1991).
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Shinzato T, Doyle E, Edelstein MA. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother.45(8), 2204–2209 (2001).
   PubMed Web of Science ®Google Scholar
• Saito A, Koga H, Shigeno H et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J. Antimicrob. Chemother.18(2), 251–260 (1986).
   PubMed Web of Science ®Google Scholar
• Blazquez Garrido RM, Espinosa Parra FJ, Alemany FL et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin. Infect. Dis.40(6), 800–806 (2005).
   PubMed Web of Science ®Google Scholar
• Mykietiuk A, Carratala J, Fernandez-Sabe N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin. Infect. Dis.40(6), 794–799 (2005).
   PubMed Web of Science ®Google Scholar
• Sabria M, Pedro-Botet ML, Gomez J et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest128(3), 1401–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Haranaga S, Tateyama M, Higa F et al. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern. Med.46(7), 353–357 (2007).
   PubMed Web of Science ®Google Scholar
• Yu VL, Greenberg RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest125(6), 2135–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Grau S, Antonio JM, Ribes E, Salvado M, Garces JM, Garau J. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int. J. Antimicrob. Agents28(3), 249–252 (2006).
   PubMed Web of Science ®Google Scholar
• Martin SJ, Pendland SL, Chen C, Schreckenberger P, Danziger LH. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Antimicrob. Agents Chemother.40(6), 1419–1421 (1996).
   PubMed Web of Science ®Google Scholar
• Nakamura S, Yanagihara K, Izumikawa K et al. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila. J. Infect.59(3), 222–224 (2009).
   PubMedGoogle Scholar
• Eaton D, Meiklejohn G, van Herick W. Studies on the etiology of primary atypical pneumonia: a filterable agent transmissible to cotton rats, hamsters, and chick embryos. J. Exp. Med.79(6), 649–668 (1944).
   PubMedGoogle Scholar
• Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol. Rev.32(6), 956–973 (2008).
   PubMed Web of Science ®Google Scholar
• Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev.17(4), 697–728 (2004).
   PubMed Web of Science ®Google Scholar
• Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. Microb. Pathog.29(5), 301–309 (2000).
   PubMed Web of Science ®Google Scholar
• Falguera M, Sacristan O, Nogues A et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch. Intern. Med.161(15), 1866–1872 (2001).
   PubMed Web of Science ®Google Scholar
• Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology9(1), 109–114 (2004).
   PubMed Web of Science ®Google Scholar
• Marston BJ, Plouffe JF, File TM Jr et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med.157(15), 1709–1718 (1997).
   PubMed Web of Science ®Google Scholar
• Sliman JA, Metzgar D, Asseff DC, Coon RG, Faix DJ, Lizewski S. Outbreak of acute respiratory disease caused by Mycoplasma pneumoniae on board a deployed U.S. navy ship. J. Clin. Microbiol.47(12), 4121–4123 (2009).
   PubMedGoogle Scholar
• Walter ND, Grant GB, Bandy U et al. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness. J. Infect. Dis.198(9), 1365–1374 (2008).
   PubMed Web of Science ®Google Scholar
• De Vos M, Van der Straeten M, Druyts E. Mycoplasma pneumoniae as a cause of pneumonia, lung abscess and pleural effusion: a case report. Infection4(1 Suppl.), 58–59 (1976).
   PubMedGoogle Scholar
• Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch. Intern. Med.153(4), 488–494 (1993).
   PubMedGoogle Scholar
• Siegler DI. Lung abscess associated with Mycoplasma pneumoniae infection. Br. J. Dis. Chest67(2), 123–127 (1973).
   PubMedGoogle Scholar
• O’Sullivan MV, Isbel NM, Johnson DW et al. Disseminated pyogenic Mycoplasma pneumoniae infection in a renal transplant recipient, detected by broad-range polymerase chain reaction. Clin. Infect. Dis.39(9), e98–e99 (2004).
   PubMedGoogle Scholar
• Ozaki T, Nishimura N, Ahn J et al. Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia in children, and the antimicrobial susceptibility of the isolates. J. Infect. Chemother.13(4), 204–207 (2007).
   PubMedGoogle Scholar
• Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin. Diagn. Lab. Immunol.11(5), 862–867 (2004).
   PubMedGoogle Scholar
• Csango PA, Pedersen JE, Hess RD. Comparison of four Mycoplasma pneumoniae IgM-, IgG- and IgA-specific enzyme immunoassays in blood donors and patients. Clin. Microbiol. Infect.10(12), 1094–1098 (2004).
   PubMedGoogle Scholar
• Michelow IC, Olsen K, Lozano J, Duffy LB, McCracken GH, Hardy RD. Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community-acquired pneumonia. J. Clin. Microbiol.42(7), 3339–3341 (2004).
   PubMedGoogle Scholar
• Pitcher D, Chalker VJ, Sheppard C, George RC, Harrison TG. Real-time detection of Mycoplasma pneumoniae in respiratory samples with an internal processing control. J. Med. Microbiol.55(Pt 2), 149–155 (2006).
   PubMed Web of Science ®Google Scholar
• Templeton KE, Scheltinga SA, Graffelman AW et al. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J. Clin. Microbiol.41(9), 4366–4371 (2003).
   PubMed Web of Science ®Google Scholar
• Raty R, Ronkko E, Kleemola M. Sample type is crucial to the diagnosis of Mycoplasma pneumoniae pneumonia by PCR. J. Med. Microbiol.54(Pt 3), 287–291 (2005).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother.41(9), 1965–1972 (1997).
   PubMed Web of Science ®Google Scholar
• Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother.46(6), 1746–1754 (2002).
   PubMed Web of Science ®Google Scholar
• Gavranich JB, Chang AB. Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst. Rev.3, CD004875 (2005).
   Google Scholar
• Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J.17(10), 865–871 (1998).
   PubMed Web of Science ®Google Scholar
• Kogan R, Martinez MA, Rubilar L et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr. Pulmonol.35(2), 91–98 (2003).
   PubMed Web of Science ®Google Scholar
• Wubbel L, Muniz L, Ahmed A et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr. Infect. Dis. J.18(2), 98–104 (1999).
   PubMed Web of Science ®Google Scholar
• Ishida K, Kaku M, Irifune K et al.In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob. Agents Chemother.38(4), 790–798 (1994).
   PubMed Web of Science ®Google Scholar
• Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr. Infect. Dis. J.14(6), 471–477 (1995).
   PubMed Web of Science ®Google Scholar
• Cassell GH, Drnec J, Waites KB et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. J. Antimicrob. Chemother.27(Suppl. A), 47–59 (1991).
   PubMed Web of Science ®Google Scholar
• Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother.25(Suppl. A), 123–126 (1990).
   PubMed Web of Science ®Google Scholar
• Schonwald S, Skerk V, Petricevic I, Car V, Majerus-Misic L, Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. J. Clin. Microbiol. Infect. Dis.10(10), 877–880 (1991).
   PubMed Web of Science ®Google Scholar
• Schonwald S, Kuzman I, Oreskovic K et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome – a randomized study. Infection27(3), 198–202 (1999).
   PubMedGoogle Scholar
• Niitu Y, Hasegawa S, Suetake T, Kubota H, Komatsu S, Horikawa M. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr.76(3), 438–443 (1970).
   PubMedGoogle Scholar
• Stopler T, Gerichter CB, Branski D. Antibiotic-resistant mutants of Mycoplasma pneumoniae. Isr. J. Med. Sci.16(3), 169–173 (1980).
   PubMedGoogle Scholar
• Stopler T, Branski D. Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B. J. Antimicrob. Chemother.18(3), 359–364 (1986).
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Narita M, Okazaki N et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother.48(12), 4624–4630 (2004).
   PubMed Web of Science ®Google Scholar
• Morozumi M, Hasegawa K, Kobayashi R et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother.49(6), 2302–2306 (2005).
   PubMed Web of Science ®Google Scholar
• Morozumi M, Iwata S, Hasegawa K et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob. Agents Chemother.52(1), 348–350 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yamazaki T, Narita M et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother.50(2), 709–712 (2006).
   PubMed Web of Science ®Google Scholar
• Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J. Clin. Microbiol.45(11), 3534–3539 (2007).
   PubMed Web of Science ®Google Scholar
• Critchley IA, Jones ME, Heinze PD et al.In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin. Microbiol. Infect.8(4), 214–221 (2002).
   PubMed Web of Science ®Google Scholar
• Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob. Agents Chemother.52(10), 3542–3549 (2008).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Schlemmer B, Garau J, Cupo M, Young C. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother.48(1), 67–74 (2001).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J. Antimicrob. Chemother.60(1), 112–120 (2007).
   PubMed Web of Science ®Google Scholar
• Patel T, Pearl J, Williams J, Haverstock D, Church D. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respir. Med.94(2), 97–105 (2000).
   PubMed Web of Science ®Google Scholar
• Bebear CM, Bove JM, Bebear C, Renaudin J. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob. Agents Chemother.41(2), 269–273 (1997).
   PubMed Web of Science ®Google Scholar
• Bebear CM, Renaudin H, Charron A, Bove JM, Bebear C, Renaudin J. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob. Agents Chemother.42(9), 2304–2311 (1998).
   PubMed Web of Science ®Google Scholar
• Gruson D, Pereyre S, Renaudin H, Charron A, Bebear C, Bebear CM. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob. Agents Chemother.49(3), 1190–1193 (2005).
   PubMed Web of Science ®Google Scholar
• Bebear CM, Renaudin J, Charron A et al. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob. Agents Chemother.43(4), 954–956 (1999).
   PubMed Web of Science ®Google Scholar
• Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin. Microbiol. Infect.9(7), 691–703 (2003).
   PubMed Web of Science ®Google Scholar
• Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin. Ther.26(1), 48–62 (2004).
   PubMed Web of Science ®Google Scholar
• Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int. J. Clin. Pract.57(5), 377–384 (2003).
   PubMed Web of Science ®Google Scholar
• Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother.54(2), 515–523 (2004).
   PubMed Web of Science ®Google Scholar
• Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N. Engl. J. Med.315(3), 161–168 (1986).
   PubMed Web of Science ®Google Scholar
• Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J. Infect. Dis.151(5), 832–839 (1985).
   PubMed Web of Science ®Google Scholar
• Dwyer RS, Treharne JD, Jones BR, Herring J. Chlamydial infection. Results of micro-immunofluorescence tests for the detection of type-specific antibody in certain chlamydial infections. Br. J. Vener. Dis.48(6), 452–459 (1972).
   PubMedGoogle Scholar
• Grayston JT, Kuo CC, Campbell LA. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int. J. Syst. Bacteriol.39, 88–90 (1989).
   Google Scholar
• Blasi F, Tarsia P, Aliberti S. Chlamydophila pneumoniae. Clin. Microbiol. Infect.15(1), 29–35 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin. Infect. Dis.44(4), 568–576 (2007).
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Peeling RW, Reid T, De Carolis E. Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur. Respir. J.21(5), 779–784 (2003).
   PubMedGoogle Scholar
• Hammerschlag MR, Chirgwin K et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin. Infect. Dis.14(1), 178–182 (1992).
   PubMed Web of Science ®Google Scholar
• Comandini UV, Maggi P, Santopadre P, Monno R, Angarano G, Vullo V. Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus. Eur. J. Clin. Microbiol. Infect. Dis.16(10), 720–726 (1997).
   PubMedGoogle Scholar
• Nakashima K, Tanaka T, Kramer MH et al. Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999–2000. Infect. Control Hosp. Epidemiol.27(11), 1171–1177 (2006).
   PubMedGoogle Scholar
• Balis E, Boufas A, Iliopoulos I, Legakis NJ, Zerva L. Severe community-acquired pneumonia with acute hypoxemic respiratory failure due to primary infection with Chlamydia pneumoniae in a previously healthy adult. Clin. Infect. Dis.36(12), e155–e157 (2003).
   PubMedGoogle Scholar
• Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjala H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax51(2), 185–189 (1996).
   PubMed Web of Science ®Google Scholar
• Roblin PM, Dumornay W, Hammerschlag MR. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol.30(8), 1968–1971 (1992).
   PubMed Web of Science ®Google Scholar
• Dowell SF, Peeling RW, Boman J et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin. Infect. Dis.33(4), 492–503 (2001).
   PubMed Web of Science ®Google Scholar
• Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob. Agents Chemother.33(9), 1634–1635 (1989).
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother.36(7), 1573–1574 (1992).
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob. Agents Chemother.36(3), 682–683 (1992).
   PubMedGoogle Scholar
• Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest103(3), 697–701 (1993).
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob. Agents Chemother.44(5), 1409 (2000).
   PubMed Web of Science ®Google Scholar
• Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob. Agents Chemother.42(1), 194–196 (1998).
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR. Advances in the management of Chlamydia pneumoniae infections. Expert Rev. Anti Infect. Ther.1(3), 493–503 (2003).
   PubMedGoogle Scholar
• Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob. Agents Chemother.38(7), 1588–1589 (1994).
   PubMed Web of Science ®Google Scholar
• Ritter J. Beitrag zur Frage des Pneumotyphus [eine Hausepidemie in Uster (Schweiz) betreffend]. Deutsches Archiv für Klinische Medizin25, 53–96 (1880).
   Google Scholar
• Beeckman DS, Vanrompay DC. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin. Microbiol. Infect.15(1), 11–17 (2009).
   PubMed Web of Science ®Google Scholar
• Harkinezhad T, Geens T, Vanrompay D. Chlamydophila psittaci infections in birds: a review with emphasis on zoonotic consequences. Vet. Microbiol.135(1–2), 68–77 (2009).
   PubMed Web of Science ®Google Scholar
• Gaede W, Reckling KF, Dresenkamp B et al.Chlamydophila psittaci infections in humans during an outbreak of psittacosis from poultry in Germany. Zoonoses Public Health55(4), 184–188 (2008).
   PubMed Web of Science ®Google Scholar
• Laroucau K, De Barbeyrac B, Vorimore F et al. Chlamydial infections in duck farms associated with human cases of psittacosis in France. Vet. Microbiol.135(1–2), 82–89 (2009).
   PubMed Web of Science ®Google Scholar
• Verminnen K, Duquenne B, De Keukeleire D et al. Evaluation of a Chlamydophila psittaci infection diagnostic platform for zoonotic risk assessment. J. Clin. Microbiol.46(1), 281–285 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes C, Maharg P, Rosario P et al. Possible nosocomial transmission of psittacosis. Infect. Control Hosp. Epidemiol.18(3), 165–168 (1997).
   PubMed Web of Science ®Google Scholar
• Barnes RC. Laboratory diagnosis of human chlamydial infections. Clin. Microbiol. Rev.2(2), 119–136 (1989).
   PubMed Web of Science ®Google Scholar
• Haralambieva I, Iankov I, Petrov D, Ivanova R, Kamarinchev B, Mitov I. Cross-reaction between the genus-specific lipopolysaccharide antigen of Chlamydia spp. and the lipopolysaccharides of Porphyromonas gingivalis, Escherichia coli O119 and Salmonella newington: implications for diagnosis. Diagn. Microbiol. Infect. Dis.41(3), 99–106 (2001).
   PubMed Web of Science ®Google Scholar
• Messmer TO, Skelton SK, Moroney JF, Daugharty H, Fields BS. Application of a nested, multiplex PCR to psittacosis outbreaks. J. Clin. Microbiol.35(8), 2043–2046 (1997).
   PubMed Web of Science ®Google Scholar
• Van Loock M, Verminnen K, Messmer TO, Volckaert G, Goddeeris BM, Vanrompay D. Use of a nested PCR-enzyme immunoassay with an internal control to detect Chlamydophila psittaci in turkeys. BMC Infect. Dis.5, 76 (2005).
   PubMed Web of Science ®Google Scholar
• Donati M, Rodriguez FM, Olmo A, D’Apote L, Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J. Antimicrob. Chemother.43(6), 825–827 (1999).
   PubMed Web of Science ®Google Scholar
• Greub G. Parachlamydia acanthamoebae, an emerging agent of pneumonia. Clin. Microbiol. Infect.15(1), 18–28 (2009).
   PubMed Web of Science ®Google Scholar
• Corsaro D, Greub G. Pathogenic potential of novel Chlamydiae and diagnostic approaches to infections due to these obligate intracellular bacteria. Clin. Microbiol. Rev.19(2), 283–297 (2006).
   PubMed Web of Science ®Google Scholar
• Greub G, Mege JL, Raoult D. Parachlamydia acanthamoebae enters and multiplies within human macrophages and induces their apoptosis [corrected]. Infect. Immun.71(10), 5979–5985 (2003).
   PubMed Web of Science ®Google Scholar
• Greub G, Mege JL, Gorvel JP, Raoult D, Meresse S. Intracellular trafficking of Parachlamydia acanthamoebae. Cell. Microbiol.7(4), 581–589 (2005).
   PubMed Web of Science ®Google Scholar
• Kahane S, Dvoskin B, Friedman MG. The role of monocyte/macrophages as vehicles of dissemination of Simkania negevensis: an in vitro simulation model. FEMS Immunol. Med. Microbiol.52(2), 219–227 (2008).
   PubMedGoogle Scholar
• Casson N, Entenza JM, Borel N, Pospischil A, Greub G. Murine model of pneumonia caused by Parachlamydia acanthamoebae. Microb. Pathog.45(2), 92–97 (2008).
   PubMedGoogle Scholar
• Friedman MG, Galil A, Greenberg S, Kahane S. Seroprevalence of IgG antibodies to the chlamydia-like microorganism ‘Simkania Z’ by ELISA. Epidemiol. Infect.122(1), 117–123 (1999).
   PubMed Web of Science ®Google Scholar
• Greenberg D, Banerji A, Friedman MG, Chiu CH, Kahane S. High rate of Simkania negevensis among Canadian inuit infants hospitalized with lower respiratory tract infections. Scand. J. Infect. Dis.35(8), 506–508 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar S, Kohlhoff SA, Gelling M et al. Infection with Simkania negevensis in Brooklyn, New York. Pediatr. Infect. Dis. J.24(11), 989–992 (2005).
   PubMed Web of Science ®Google Scholar
• Fasoli L, Paldanius M, Don M et al.Simkania negevensis in community-acquired pneumonia in Italian children. Scand. J. Infect. Dis.40(3), 269–272 (2008).
   PubMed Web of Science ®Google Scholar
• Heiskanen-Kosma T, Paldanius M, Korppi M. Simkania negevensis may be a true cause of community acquired pneumonia in children. Scand. J. Infect. Dis.40(2), 127–130 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman D, Kahane S, Lieberman D, Friedman MG. Pneumonia with serological evidence of acute infection with the Chlamydia-like microorganism “Z”. Am. J. Respir. Crit. Care Med.156(2 Pt 1), 578–582 (1997).
   PubMed Web of Science ®Google Scholar
• Nascimento-Carvalho CM, Cardoso MR, Paldanius M et al.Simkania negevensis infection among Brazilian children hospitalized with community-acquired pneumonia. J. Infect.58(3), 250–253 (2009).
   PubMed Web of Science ®Google Scholar
• Casson N, Posfay-Barbe KM, Gervaix A, Greub G. New diagnostic real-time PCR for specific detection of Parachlamydia acanthamoebae DNA in clinical samples. J. Clin. Microbiol.46(4), 1491–1493 (2008).
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Raoult D, La Scola B, Birtles RJ, de Carolis E. Legionella-like and other amoebal pathogens as agents of community-acquired pneumonia. Emerg. Infect. Dis.7(6), 1026–1029 (2001).
   PubMedGoogle Scholar
• Casson N, Michel R, Muller KD, Aubert JD, Greub G. Protochlamydia naegleriophila as etiologic agent of pneumonia. Emerg. Infect. Dis.14(1), 168–172 (2008).
   PubMedGoogle Scholar
• Haider S, Collingro A, Walochnik J, Wagner M, Horn M. Chlamydia like bacteria in respiratory samples of community-acquired pneumonia patients. FEMS Microbiol. Lett.281(2), 198–202 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman MG, Dvoskin B, Kahane S. Infections with the chlamydia-like microorganism Simkania negevensis, a possible emerging pathogen. Microbes Infect.5(11), 1013–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Greub G, Berger P, Papazian L, Raoult D. Parachlamydiaceae as rare agents of pneumonia. Emerg. Infect. Dis.9(6), 755–756 (2003).
   PubMed Web of Science ®Google Scholar
• Casson N, Greub G. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes. Int. J. Antimicrob. Agents27(6), 541–544 (2006).
   PubMed Web of Science ®Google Scholar
• Maurin M, Bryskier A, Raoult D. Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae. Antimicrob. Agents Chemother.46(9), 3065–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Derrick EH. “Q” fever, a new fever entity: clinical features, diagnosis and laboratory investigation. Rev. Infect. Dis.5(4), 790–800 (1983).
   PubMedGoogle Scholar
• Baca OG, Paretsky D. Q fever and Coxiella burnetii: a model for host-parasite interactions. Microbiol. Rev.47(2), 127–149 (1983).
   PubMedGoogle Scholar
• Fishbein DB, Raoult D. A cluster of Coxiella burnetii infections associated with exposure to vaccinated goats and their unpasteurized dairy products. Am. J. Trop. Med. Hyg.47(1), 35–40 (1992).
   PubMed Web of Science ®Google Scholar
• Harman JB. Q fever in Great Britain; clinical account of eight cases. Lancet2(6588), 1028–1030 (1949).
   PubMedGoogle Scholar
• Rolain JM, Gouriet F, Brouqui P et al. Concomitant or consecutive infection with Coxiella burnetii and tickborne diseases. Clin. Infect. Dis.40(1), 82–88 (2005).
   PubMed Web of Science ®Google Scholar
• Maurin M, Raoult D. Q fever. Clin. Microbiol. Rev.12(4), 518–553 (1999).
   PubMed Web of Science ®Google Scholar
• Tissot Dupont H, Raoult D, Brouqui P et al. Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. Am. J. Med.93(4), 427–434 (1992).
   PubMed Web of Science ®Google Scholar
• Dupuis G, Petite J, Peter O, Vouilloz M. An important outbreak of human Q fever in a Swiss Alpine valley. Int. J. Epidemiol.16(2), 282–287 (1987).
   PubMed Web of Science ®Google Scholar
• Schimmer B, Morroy G, Dijkstra F et al. Large ongoing Q fever outbreak in the south of The Netherlands, 2008. Euro. Surveill.13(31), pii; 18939 (2008).
   Google Scholar
• Marrie TJ. Coxiella burnetii pneumonia. Eur. Respir. J.21(4), 713–719 (2003).
   PubMedGoogle Scholar
• Oddo M, Jolidon RM, Peter O, Poli S, Cometta A. Q fever pneumonia complicated by acute respiratory distress syndrome. Intensive Care Med.27(3), 615 (2001).
   PubMedGoogle Scholar
• Schneeberger PM, Hermans MH, van Hannen EJ, Schellekens JJ, Leenders AC, Wever PC. Real-time PCR on serum samples is indispensable for early diagnosis of acute Q-fever. Clin. Vaccine Immunol.17(2), 286–290 (2009).
   PubMedGoogle Scholar
• Yeaman MR, Mitscher LA, Baca OG. In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob. Agents Chemother.31(7), 1079–1084 (1987).
   PubMed Web of Science ®Google Scholar
• Caron F, Meurice JC, Ingrand P et al. Acute Q fever pneumonia: a review of 80 hospitalized patients. Chest114(3), 808–813 (1998).
   PubMedGoogle Scholar
• Perez-del-Molino A, Aguado JM, Riancho JA, Sampedro I, Matorras P, Gonzalez-Macias J. Erythromycin and the treatment of Coxiella burnetii pneumonia. J. Antimicrob. Chemother.28(3), 455–459 (1991).
   PubMed Web of Science ®Google Scholar
• Sobradillo V, Zalacain R, Capelastegui A, Uresandi F, Corral J. Antibiotic treatment in pneumonia due to Q fever. Thorax47(4), 276–278 (1992).
   PubMed Web of Science ®Google Scholar
• Welti M, Jaton K, Altwegg M, Sahli R, Wenger A, Bille J. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn. Microbiol. Infect. Dis.45(2), 85–95 (2003).
   PubMed Web of Science ®Google Scholar
• Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr. Infect. Dis. J.22(12), 1128–1132 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin. Infect. Dis.37(3), 376–381 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med.346(10), 747–750 (2002).
   PubMed Web of Science ®Google Scholar
• Leibovitz E. The use of fluoroquinolones in children. Curr. Opin. Pediatr.18(1), 64–70 (2006).
   PubMed Web of Science ®Google Scholar